about
Impact of Inflammation on Myeloproliferative Neoplasm Symptom DevelopmentSex-based memory advantages and cognitive aging: a challenge to the cognitive reserve construct?Optimized preload leakage-correction methods to improve the diagnostic accuracy of dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging in posttreatment gliomasTransoral laser microsurgery followed by radiation therapy for oropharyngeal tumors: the Mayo Clinic Arizona experience.Laparoscopic radical nephrectomy for very large renal tumors (> or =10 cm): is there a size limit?Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831.Multicenter phase 2 study of combination therapy with ruxolitinib and danazol in patients with myelofibrosis.North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancerDepressive symptoms in healthy apolipoprotein E ε4 carriers and noncarriers: a longitudinal study.IAP antagonists induce anti-tumor immunity in multiple myeloma.Soluble human epidermal growth factor receptor 2 (HER2) levels in patients with HER2-positive breast cancer receiving chemotherapy with or without trastuzumab: results from North Central Cancer Treatment Group adjuvant trial N9831C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial.Cerebrovascular risk factors and preclinical memory decline in healthy APOE ε4 homozygotesLongitudinal modeling of frontal cognition in APOE ε4 homozygotes, heterozygotes, and noncarriersGenomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.Neoadjuvant chemoradiation compared to neoadjuvant radiation alone and surgery alone for Stage II and III soft tissue sarcoma of the extremities.Public perceptions of presymptomatic testing for Alzheimer diseaseMalignant melanoma in the elderly: different regional disease and poorer prognosis.Breast medical oncologists' use of standard prognostic factors to predict a 21-gene recurrence scorePredictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteriaQuality of life and disease understanding: impact of attending a patient-centered cancer symposiumEndpoint comparison for bone mineral density measurements in North Central Cancer Treatment Group cancer clinical trials N02C1 and N03CC (Alliance)MUC1 Vaccines, Comprised of Glycosylated or Non-Glycosylated Peptides or Tumor-Derived MUC1, Can Circumvent Immunoediting to Control Tumor Growth in MUC1 Transgenic Mice.Phase Ib/II trial of CYKLONE (cyclophosphamide, carfilzomib, thalidomide and dexamethasone) for newly diagnosed myelomaPredictive testing for Alzheimer's disease: suicidal ideation in healthy participantsThe relationship between quantitative human epidermal growth factor receptor 2 gene expression by the 21-gene reverse transcriptase polymerase chain reaction assay and adjuvant trastuzumab benefit in Alliance N9831.The impact of concomitant medication use on patient eligibility for phase I cancer clinical trials.Multidisciplinary Shared Decision Making in the Management of Ductal Carcinoma In Situ of the Breast.Impact of Software Modeling on the Accuracy of Perfusion MRI in Glioma.Genomic amplification of 9p24.1 targeting JAK2, PD-L1, and PD-L2 is enriched in high-risk triple negative breast cancer.Effects of carpal tunnel syndrome on adaptation of multi-digit forces to object mass distribution for whole-hand manipulation.Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005).RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer.A Phase Ib Study of the combination of the Aurora Kinase Inhibitor Alisertib (MLN8237) and Bortezomib in Relapsed Multiple Myeloma.Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial.Fibrillar amyloid correlates of preclinical cognitive decline.N0539 phase II trial of fulvestrant and bevacizumab in patients with metastatic breast cancer previously treated with an aromatase inhibitor: a North Central Cancer Treatment Group (now Alliance) trial.Impact of c-MYC protein expression on outcome of patients with early-stage HER2+ breast cancer treated with adjuvant trastuzumab NCCTG (alliance) N9831.A phase III randomized, double-blind, placebo-controlled trial of gabapentin in the management of hot flashes in men (N00CB).Factors influencing time between biopsy and definitive surgery for malignant melanoma: do they impact clinical outcome?
P50
Q26779947-5158DFD4-FB63-4B8E-BB0A-433FD2FFF369Q27302017-BB463E40-7BDC-4134-A932-3E08892C6F41Q30419061-9AE0DBAC-09B9-494F-8170-F424C67152AFQ31114002-A3BC9080-475D-419A-A716-37001EE87EF9Q33396824-188FEE08-0D58-4368-BC39-C987D5605E3FQ33427353-8269BBD5-BE96-48FD-B9E8-F13B777AC922Q33442961-76DD1D6C-C8B0-4BAA-BF63-22AF7D7AEE6BQ33618149-C69AE843-C3FC-420D-A4C8-22537DF56947Q33899629-A459C21B-D9BE-4FA7-B1B8-F4C48A784C3BQ33914862-089F213D-30B4-48F8-90E7-2AFD1CD376D9Q34020878-DCBFF37F-1B19-46CF-B5FC-8AF94909F494Q34667820-DA900427-F00C-4628-A5F7-034F8DAB00C7Q34743183-F6678756-578C-4DA8-92FA-405CB15D5C89Q34922644-D8540707-CDDC-4674-BAE2-346B3A834C64Q35102480-59A499AF-53A8-4AAB-B6FA-45AD3AB5FB42Q35206145-C0A34D08-8DD5-4646-8025-9EEC78BEA6E1Q35206422-42EE0C54-2B39-46E4-AF23-8647D2CB56C6Q35542768-DA9BA83E-5430-4AC4-AA4F-DB8D66F216E1Q35584364-2E4AE1CF-80CF-4E26-8DB7-FC5079FA6F65Q35677457-B02734F8-24C0-40D0-91A4-78399A511455Q35755358-C10F04F4-0EE8-4EAA-A6C5-31C99F8254C6Q35793168-F6FAC0D2-8CE8-442B-876A-A3767B49F12EQ35898801-495A7FE6-B4E0-45A3-82F6-481C4DFEDF2EQ35907767-B89A28CC-DE16-4FA8-945E-61A545068599Q35977212-883C026B-DFD1-46AD-901A-CD7D9BAFA5A9Q36110190-0E74133F-B643-4100-9961-57EE947E3B43Q36210439-406E8694-99E9-453A-9B9F-2CD27CB16446Q36299984-E6714594-4F98-4AB4-A8B0-95AA3B73C81DQ36378153-D8EB179D-2A03-425F-BF4E-F7B7012A0C54Q36413493-BDB5266A-605D-4437-8689-F70C636942B8Q36526892-353BB541-6774-48C6-AD80-A9683662A854Q36649356-0E555DEF-68FB-4B15-8208-E5364EA96E31Q36718403-FA685D2F-679F-4CB2-BC1E-4FDFCCD787F1Q36763982-0D522D99-7F56-4DDE-8290-0812213CCEDFQ36914459-C82AFF91-2C38-4917-B402-0A953FA76EF8Q37018071-F869BC75-2F11-4839-9E0A-E798F998BAE1Q37200495-16AA0D09-020D-4793-9A9C-33E01269556BQ37246798-B2521981-E827-4C1C-B88D-49412C18EF17Q37321785-6A0C236F-2968-49FD-8806-DDDF7E382B3CQ37354407-52A6F5B2-2085-4580-965E-343E19948A8A
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Amylou Dueck
@en
Amylou Dueck
@nl
type
label
Amylou Dueck
@en
Amylou Dueck
@nl
prefLabel
Amylou Dueck
@en
Amylou Dueck
@nl
P31
P496
0000-0002-9912-1085